N6-Ethyl-2’-beta-C-ethynyl adenosine

N6-Ethyl-2’-beta-C-ethynyl adenosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. N6-Ethyl-2’-beta-C-ethynyl adenosine is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

UNSPSC

12352005

Target

Nucleoside Antimetabolite/Analog

Type

Oligonucleotides

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/n6-ethyl-2-beta-c-ethynyl-adenosine.html

Solubility

10 mM in DMSO

Smiles

O[C@H]1[C@](O)(C#C)[C@H](N(C=N2)C3=C2C(NCC)=NC=N3)O[C@@H]1CO

Molecular Formula

C14H17N5O4

Molecular Weight

319.32

References & Citations

[1]Man S, et al. Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 2021 Jun;26 (6) :1490-1500.|[2]Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18 (23) :3373-88.